FUNDAMENTALS |
MarketCap: |
283 599 mill
|
EPS: |
3.36
|
P/E: |
47.80
|
Earnings Date: |
Jul 25, 2024 |
SharesOutstanding: |
1 765.87 mill
|
Avg Daily Volume: |
5.73 mill
|
RATING
2024-05-09 |
S
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Buy
|
|
DE: |
Strong Buy
|
|
P/E: |
Strong Buy
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
3.10x
|
Company: PE 47.80 | sector: PE 15.43
|
PE RATIO: COMPANY / INDUSTRY |
0.98x
|
Company: PE 47.80 | industry: PE 48.81
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 157.35 - 163.95
( +/- 2.05%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-05-03 | Davis Jennifer L. | Buy | 1 322 | Common Stock, $0.01 par value |
2024-05-03 | Quaggin Susan E | Buy | 1 322 | Common Stock, $0.01 par value |
2024-05-03 | Rapp Edward J | Buy | 1 322 | Common Stock, $0.01 par value |
2024-05-03 | Alpern Robert J | Buy | 1 322 | Common Stock, $0.01 par value |
2024-05-03 | Freyman Thomas C | Buy | 1 322 | Common Stock, $0.01 par value |
INSIDER POWER |
-22.06
|
Last
100 transactions |
Buy:
589 844 | Sell:
912 577 |
Forecast:
15:27 - $160.66
Live Trading Signals (every 1 min)
Forecast
1: 13:57 - $160.59
Forecast 2: 14:47 - $160.61
Forecast 3: 15:27 - $160.66
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$160.60 (0.09% )
|
Volume |
1.343 mill
|
Avg. Vol. |
5.73 mill
|
% of Avg. Vol |
23.45 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For ABBV
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.